February 25, 2025
Introduction
The year 2024 marked a critical transition in oncology, as the field moved from incremental advancements to transformative breakthroughs. The longstanding challenges in treating solid tumors began to be overcome, with cellular therapies, targeted drugs, and immune microenvironment modulation advancing on multiple technological fronts. The integration of gene editing technologies and AI-driven drug discovery has dramatically increased efficiency in target identification and drug design, signaling the imminent arrival of a revolution in cancer treatment.
1. Cellular Therapy: Breaking Barriers in Solid Tumors and the Revolution of In Vivo Engineering
Key Technological Breakthroughs: Overcoming immunosuppressive tumor microenvironments and simplifying manufacturing processes
Background Challenges: Cellular therapy had long been limited to hematologic malignancies (e.g., leukemia, lymphoma), as solid tumors presented major barriers due to their immunosuppressive tumor microenvironment (TME), antigen heterogeneity, and physical barriers (such as stromal barriers). Traditional CAR-T therapies struggled with T-cell infiltration deficiency, antigen escape, and poor persistence in solid tumors.
Breakthroughs in 2024
Iovance Biotherapeutics’s Amtagvi, the first FDA-approved TIL (tumor-infiltrating lymphocyte) therapy, received accelerated approval for PD-1-resistant melanoma, demonstrating an objective response rate (ORR) of 42% and a median duration of response (DOR) of 10.4 months. Meanwhile, China’s JunSai Biotech introduced GC101TIL, the first TIL therapy that eliminates the need for lymphodepletion and IL-2 infusion. The clinical trial showed an ORR of 35.7% with no treatment-related deaths, significantly improving accessibility.
In TCR-T therapy, Adaptimmune’s Tecelra, which targets intracellular antigen MAGE-A4, demonstrated an ORR of 43% in synovial sarcoma patients, with a complete response (CR) rate of 4.5% and manageable toxicity. China’s Xiangxue Life Sciences received Breakthrough Therapy Designation for its TAEST16001 (soft tissue sarcoma therapy), achieving a Phase II ORR of 50%, breaking the monopoly of imported treatments.
In vivo CAR-T therapy saw a major breakthrough with Interius’ INT2104, which uses a lentiviral vector to generate CAR-T cells directly in the body. This shortened the treatment timeline from six weeks to a single infusion, achieving a 60% ORR in B-cell malignancies. Meanwhile, CARv3-TEAM-E therapy, targeting glioblastoma (EGFR vIII and wild-type EGFR), demonstrated tumor regression in Phase I trials, with one patient’s tumor nearly disappearing and no severe toxicities observed.
On the industrial and cost reduction front, non-viral gene editing (e.g., CRISPR) and automation significantly lowered manufacturing costs. China’s Shali Biotech’s GT101 shortened TIL production time from 21 to 14 days through automated expansion technology. However, costs remain a challenge—the total treatment expense for Amtagvi exceeded $515,000 per cycle, with an additional $30,000–50,000 for IL-2 infusions and $350,000–400,000 for ICU care. JunSai’s GC101TIL is expected to reduce treatment costs by over 90% through its simplified process.
2. Targeted Therapy: Overcoming “Undruggable” Targets and Blood-Brain Barrier Penetration
Key Technological Breakthroughs: KRAS inhibitors and targeted therapies for brain tumors
KRAS mutations, found in 90% of pancreatic cancers and 40% of colorectal cancers, had long been considered undruggable due to the lack of binding sites on the protein’s smooth surface. Brain tumor drugs, meanwhile, faced limited efficacy due to the blood-brain barrier (BBB).
Breakthroughs in 2024
KRAS-targeted therapies expanded beyond G12C mutations to pan-KRAS inhibition. Revolution Medicines’ RMC-9805, a KRAS G12D inhibitor, achieved an ORR of 30% and a disease control rate (DCR) of 80% in pancreatic cancer patients, breaking through the G12C-only paradigm. Additionally, Elicio’s ELI-002 (KRAS-targeted cancer vaccine), when combined with chemotherapy, resulted in tumor marker reductions in 84% of patients and complete tumor clearance in 24%, pioneering a new paradigm of combining targeted therapy with immunotherapy.
In brain tumor therapies, Ojemda (pan-RAF inhibitor) demonstrated an ORR of 42% in pediatric gliomas, with a median duration of response of 24 months, outperforming traditional chemotherapy. Voranigo, an IDH1/2 dual inhibitor, extended median overall survival (OS) to 28.5 months in astrocytoma patients, successfully reaching therapeutic concentrations in cerebrospinal fluid.
Clinical strategy optimization further improved outcomes. In EGFR-mutant NSCLC, AstraZeneca’s Osimertinib (LAURA trial) achieved a record-breaking increase in median progression-free survival (PFS) from 5.6 months to 39.1 months. Meanwhile, the FL-ALTER study, combining gefitinib with anlotinib (an anti-angiogenesis therapy), demonstrated a PFS of 22.1 months, validating the synergistic efficacy of targeted therapy and angiogenesis inhibition.
3. Combination Therapy: Microenvironment Remodeling and Precision Synergy
Key Technological Breakthroughs: Gut microbiome modulation and sequenced immuno-radiotherapy
Checkpoint inhibitors such as PD-1 monotherapy remain ineffective in over 70% of patients, while immunotherapy-radiotherapy combinations often result in high toxicity.
Researchers at MD Anderson discovered that Bifidobacterium enhances CD8+ T-cell activation, leading to an increase in CAR-T therapy ORR from 42% to 58% when combined with gut microbiota transplantation.
Optimizing radiotherapy-immunotherapy sequencing proved crucial. KEYNOTE-867 (SBRT + pembrolizumab trial) was terminated due to increased toxicity without survival benefits, highlighting the need for precise radiation timing and dosing. However, Sun Yat-sen University’s SACTION01 study, which combined SBRT, immunotherapy, and chemotherapy in NSCLC patients, achieved a pathological complete response (pCR) rate of 52.2%, leading to the launch of a Phase III trial.
In ADC-immunotherapy combinations, TROP2-targeted ADC sacituzumab govitecan combined with PD-L1 inhibitor KL-A167 demonstrated an ORR of 48% and a median PFS of 8.9 months in driver-negative NSCLC, further validating the dual-engine potential of ADC and immunotherapy.
4. Early Detection and Prevention: Liquid Biopsy and Multi-Cancer Interception
Liquid biopsy technology advanced significantly. Grail’s Galleri test, capable of detecting 12 types of cancer, achieved 85% sensitivity, identifying cancers 6–12 months earlier than traditional imaging. In China, Burning Rock Dx’s OverC™, covering lung and colorectal cancer, completed large-scale clinical validation with specificity exceeding 98%.
Microbiome-based cancer prevention trials launched, with studies showing that gut microbiota transplantation can modulate Th17/Treg balance, potentially reducing cancer risk in healthy individuals.
Future Outlook
The core logic behind 2024’s breakthroughs can be summarized as follows:
- Paradigm shift in solid tumor therapy—from “destruction” to “regulation”, leveraging TIL therapy for natural T-cell reprogramming and CAR-TEAM therapy for dual-target heterogeneity resistance.
- Balancing cost and efficacy—in vivo engineering (e.g., INT2104) and automation (e.g., GT101) drive affordability.
- Integrating prevention and treatment—liquid biopsy and microbiome interventions shift cancer management from “late-stage treatment” to “early interception.”
With gene editing, AI, and clinical data integration, oncology is moving toward reversible disease modulation and functional cures.
[Disclaimer] The above content reflects a summary of relevant events and does not constitute any investment advice. Information is sourced from public data, expert opinions, and BCC research. BCC Global bears no responsibility for any losses resulting from the use of this content. Investments carry risks—proceed with caution.